KRON.Kronos Bio, INC
Form 4: Kronos Bio Director Arie Belldegrun Acquires 34,000 Stock Options
Sentiment:
SEC Form 4 Filing
Director Arie Belldegrun acquired 34,000 stock options in Kronos Bio, Inc. on June 25, 2024.
Summary
- On June 25, 2024, Arie Belldegrun, a director of Kronos Bio, Inc., acquired 34,000 stock options.
- The exercise price of these options is $0.95.
- The options vest upon the earlier of the one-year anniversary of the grant date or the date of the Issuer's next annual meeting of stockholders.
- The options expire on June 24, 2034.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it is a standard regulatory filing related to stock option grants.
Positives
- The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders.
Stakeholder Impact
- The acquisition of stock options by a director may influence investor sentiment.
Key Dates
| Date | Description |
|---|---|
| 06/25/2024 | Date of transaction: Arie Belldegrun acquired 34,000 stock options. |
| 06/26/2024 | Date of filing: The Form 4 was signed on this date. |
| 06/24/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.